Metformin induces cell cycle arrest, reduced proliferation, wound healing impairment in vivo and is associated to clinical outcomes in diabetic foot ulcer patients

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Ochoa Gonzalez, Fatima ^a,b   Cervantes Villagrana, Alberto R ^b   Fernandez Ruiz, Julio C ^a   Nava Ramirez, Hilda S ^a   Hernandez Correa, Adriana C ^b   Enciso Moreno, Jose A ^a   Castañeda Delgado, Julio E ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PREVENTION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SIZE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DIABETIC FOOT; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; FOOT ULCER; HUMAN; IN VIVO STUDY; OUTCOME ASSESSMENT; WOUND CLOSURE; WOUND HEALING IMPAIRMENT; ADULT; AGED; ANIMAL; CELL CYCLE CHECKPOINT; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RAT; WISTAR RAT; WOUND HEALING;

ADULT; AGED; ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; HUMANS; MALE; METFORMIN; MIDDLE AGED; RATS; RATS, WISTAR; WOUND HEALING;

EID: 84961231063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150900     Document Type: Article

References (48)

1. Park J, Peters PA. Mortality from diabetes mellitus, 2004 to 2008: A multiple-cause-of-death analysis. Health Rep. 2014;25(3):12-6. Epub 2014/03/22. doi: 82-003-X201400311909 [pii]. PMID: 24648135.
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-49. Epub 2014/03/19. doi: S0168-8227 (13) 00385-9 [pii] doi: 10.1016/j.diabres.2013.11.002 PMID: 24630390.
3. Lee WJ, Song KH, Noh JH, Choi YJ, Jo MW. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. J Korean MedSci. 2012;27(3):255-60. Epub 2012/03/02. doi: 10.3346/jkms.2012.27.3.255 PMID: 22379335; PubMed Central PMCID: PMC3286771.
4. Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2014;105(2):151-63. Epub 2014/05/13. doi: S0168-8227 (14) 00176-4 [pii] doi: 10. 1016/j.diabres.2014.03.020 PMID: 24814877.
5. O'Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, etal. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Qual Life Res. 2011;20(6):939-43. Epub 2011/01/12. doi: 10.1007/s11136-010-9828-9 PMID: 21221816.
6. Castro-Rios A, Nevarez-Sida A, Tiro-Sanchez MT, Wacher-Rodarte N. Triggering factors of primary care costs in the years following type 2 diabetes diagnosis in Mexico. Arch Med Res. 2014;45(5):400-8. Epub 2014/05/16. doi: S0188-4409 (14) 00077-0 [pii] doi: 10.1016/j.arcmed.2014.05.002 PMID: 24825741.
7. Rodriguez Bolanos Rde L, Reynales Shigematsu LM, Jimenez Ruiz JA, Juarez Marquezy SA, Hernandez Avila M. [Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro-costing analysis]. Rev Panam Salud Publica. 2010;28(6):412-20. Epub 2011/02/11. doi: S1020-49892010001200002 [pii]. PMID: 21308167.
8. Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration and amputation: can global variation be explained? Med Clin North Am. 2013;97(5):791-805. Epub 2013/09/03. doi: S0025-7125 (13) 00049-7 [pii] doi: 10.1016/j.mcna.2013.03.008 PMID: 23992892.
9. Martins-Mendes D, Monteiro-Soares M, Boyko EJ, Ribeiro M, Barata P, Lima J, etal. The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk. J Diabetes Complications. 2014;28(5):632-8. Epub 2014/06/01. doi: S1056-8727 (14) 00126-3 [pii] doi: 10.1016/j. jdiacomp. 2014.04.011 PMID: 24877985; PubMed Central PMCID: PMC4240944.
10. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-28. Epub 2005/01/13. doi: 293/2/217 [pii] doi: 10.1001/jama.293.2.217 PMID: 15644549.
11. Won SH, Chung CY, Park MS, Lee T, Sung KH, Lee SY, etal. Risk factors associated with amputationfree survival in patient with diabetic foot ulcers. Yonsei Med J. 2014;55(5):1373-8. Epub 2014/07/23. doi: 2014091373 [pii] doi: 10.3349/ymj.2014.55.5.1373 PMID: 25048499; PubMed Central PMCID: PMC4108826.
12. Musa HG, Ahmed ME. Associated risk factors and management of chronic diabetic foot ulcers exceeding 6 months'duration. Diabet Foot Ankle. 2012;3. Epub 2012/11/03. doi: 10.3402/dfa.v3i0.18980 18980 [pii]. PMID: 23119125; PubMed Central PMCID: PMC3485402.
13. Pickwell K, Siersma V, Kars M, Apelqvist J, Bakker K, Edmonds M, etal. Predictors of lower-extremity amputation in patients with an infected diabetic foot ulcer. Diabetes Care. 2015;38(5):852-7. Epub 2015/02/11. doi: 10.2337/dc14-1598 PMID: 25665817.
14. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, De Censi A, etal. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014;7(9):867-85. Epub 2014/07/06. doi: 1940-6207. CAPR-13-0424 [pii] doi: 10.1158/1940-6207. CAPR-13-0424 PMID: 24985407; PubMed Central PMCID: PMC4154969.
15. Gandini S, Guerrieri-Gonzaga A, Puntoni M, Decensi A. Metformin and breast cancer risk. J Clin Oncol. 2013;31(7):973-4. Epub 2013/01/30. doi: JCO.2012.46.3596 [pii] doi: 10.1200/JCO.2012.46.3596 PMID: 23358989.
16. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoSONE. 2012;7(3):e33411. Epub 2012/03/27. doi: 10.1371/journal. pone.0033411 PONE-D-11-24599 [pii]. PMID: 22448244; PubMed Central PMCID: PMC3308971.
17. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, etal. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3(11):1451-61. Epub 2010/10/16. doi: 1940-6207CAPR-10-0157 [pii] doi: 10.1158/1940-6207.CAPR-10-0157 PMID: 20947488.
18. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, etal. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11(5):390-401. Epub 2010/05/07. doi: S1550-4131 (10) 00084-7 [pii] doi: 10.1016/j.cmet.2010.03.014 PMID: 20444419; PubMed Central PMCID: PMC3081779.
19. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8(1):88-96. Epub 2008/12/25. doi: 7499 [pii]. PMID: 19106626.
20. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, etal. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-86. Epub 2008/01/24. doi: 1211024 [pii] doi: 10.1038/sj.onc.1211024 PMID: 18212742.
21. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMPkinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269-73. Epub 2006/10/26. doi: 0008-5472CAN-06-1500 [pii] doi: 10.1158/0008-5472. CAN-06-1500 PMID: 17062558.
22. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. The Journal of cell biology. 1988;106(3):761-71. Epub 1988/03/01. PMID: 2450098; PubMed Central PMCID: PMC2115116.
23. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315-9. Epub 2007/04/05. doi: nprot.2006.339 [pii] doi: 10.1038/nprot.2006.339 PMID: 17406473.
24. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-5. Epub 2012/08/30. PMID: 22930834.
25. Achar RA, Silva TC, Achar E, Martines RB, Machado JL. Use of insulin-like growth factor in the healing of open wounds in diabetic and non-diabetic rats. Acta cirurgica brasileira/Sociedade Brasileira para Desenvolvimento PesquisaemCirurgia. 2014;29(2):125-31. Epub 2014/03/08. doi: 10.1590/S0102-86502014000200009 PMID: 24604317.
26. Schuler KM, Rambally BS, Di Furio MJ, Sampey BP, Gehrig PA, Makowski L, etal. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2015;4(2):161-73. Epub 2014/11/25. doi: 10.1002/cam4.353 PMID: 25417601; PubMed Central PMCID: PMC4329001.
27. Matsuzaki S, Humphries KM. Selective inhibition of deactivated mitochondrial complex I by biguanides. Biochemistry. 2015;54(11):2011-21. Epub 2015/02/27. doi: 10.1021/bi501473h PMID: 25719498; PubMed Central PMCID: PMC4440585.
28. Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC cancer. 2012;12:517. Epub 2012/11/16. doi: 10.1186/1471-2407-12-517 PMID: 23151022; PubMed Central PMCID: PMC3518152.
29. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13(5):483-91. Epub 2011/05/03. PMID: 21532889; PubMed Central PMCID: PMC3084625.
30. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-65. Epub 1998/09/22. PMID: 9742977.
31. Silvestri A, Palumbo F, Rasi I, Posca D, Pavlidou T, Paoluzi S, etal. Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions. PLoSOne. 2015;10(8):e0136250. Epub 2015/08/21. doi: 10.1371/journal.pone.0136250 PMID: 26291325; PubMed Central PMCID: PMC4546379.
32. Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014;462(3):475-87. Epub 2014/07/16. doi: BJ20140620 [pii] doi: 10.1042/BJ20140620 PMID: 25017630; PubMed Central PMCID: PMC4148174.
33. Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, etal. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem. 2014;289(40):27692-701. Epub 2014/08/22. doi: M114.592576 [pii] doi: 10.1074/jbc. M114.592576 PMID: 25143389; PubMed Central PMCID: PMC4183806.
34. Perez-Revuelta BI, Hettich MM, Ciociaro A, Rotermund C, Kahle PJ, Krauss S, et al. Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell death & disease. 2014;5:e1209. Epub 2014/05/09. doi: cddis2014175 [pii] doi: 10.1038/cddis.2014.175 PMID: 24810045; PubMed Central PMCID: PMC4047877.
35. Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway. Pharm Biol. 2015:1-6. Epub 2015/08/26. doi: 10. 3109/13880209.2015.1057652 PMID: 26305116.
36. Quattrini I, Conti A, Pazzaglia L, Novello C, Ferrari S, Picci P, etal. Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. Oncol Rep. 2014;31(1):370-5. Epub 2013/11/21. doi: 10.3892/or.2013.2862 PMID: 24253938.
37. Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, et al. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep. 2013;30(5):2449-57. Epub 2013/09/07. doi: 10.3892/or.2013.2718 PMID: 24008375.
38. Peyton KJ, Liu XM, Yu Y, Yates B, Durante W. Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells. The Journal of pharmacology and experimental therapeutics. 2012;342(3):827-34. Epub 2012/06/16. doi: 10.1124/jpet.112.194712 PMID: 22700432; PubMed Central PMCID: PMC3422516.
39. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015;112(6):1809-14. Epub 2015/01/28. doi: 1417636112 [pii] doi: 10.1073/pnas.1417636112 PMID: 25624476; PubMed Central PMCID: PMC4330733.
40. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, etal. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. ArteriosclerThromb Vasc Biol. 2006;26(3):611-7. Epub 2005/12/31. doi: 01. ATV.0000201938.78044.75 [pii] doi: 10.1161/01. ATV. 0000201938.78044.75 PMID: 16385087.
41. Berger E, Vega N, Weiss-Gayet M, Geloen A. Gene Network Analysis of Glucose Linked Signaling Pathways and Their Role in Human Hepatocellular Carcinoma Cell Growth and Survival in HuH7 and HepG2Cell Lines. Biomed Res Int. 2015;2015:821761. Epub 2015/09/18. doi: 10.1155/2015/821761 PMID: 26380295; PubMed Central PMCID: PMC4561296.
42. Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. SciTransl Med. 2014;6(265):265sr6. Epub 2014/12/05. doi: 10.1126/scitranslmed. 3009337 PMID: 25473038.
43. Lee CH, Hsieh MJ, Chang SH, Lin YH, Liu SJ, Lin TY, etal. Enhancement of diabetic wound repair using biodegradable nanofibrous metformin-eluting membranes: in vitro and in vivo. ACS applied materials & interfaces. 2014;6(6):3979-86. Epub 2014/02/27. doi: 10.1021/am405329g PMID: 24568239.
44. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clinical science. 2012;122(6):253-70. Epub 2011/11/29. doi: 10. 1042/CS20110386 PMID: 22117616; PubMed Central PMCID: PMC3398862.
45. Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, et al. Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PLoSOne. 2015;10(9):e0135858. Epub 2015/09/12. doi: 10.1371/journal.pone.0135858 PMID: 26360050; PubMed Central PMCID: PMC4567351.
46. Wang ZS, Liu XH, Wang M, Jiang GJ, Qiu T, Chen ZY, etal. Metformin attenuated the inflammation after renal ischemia/reperfusion and suppressed apoptosis of renal tubular epithelial cell in rats. Acta cirurgicabrasileira/Sociedade Brasileirapara Desenvolvimento Pesquisaem Cirurgia. 2015;30(9):617-23. Epub 2015/10/16. doi: 10.1590/S0102-865020150090000006 PMID: 26465106.
47. Chen M, Zhang J, Hu F, Liu S, Zhou Z. Metformin affects the characteristics of HepG2 cells by regulating macrophage polarization in a co-culture microenvironment. Diabetes/metabolism research and reviews. 2015. Epub 2015/10/16. doi: 10.1002/dmrr.2761 PMID: 26467463.
48. Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, etal. Metformin as adjunct antituberculosis therapy. SciTransl Med. 2014;6(263):263ra159. Epub 2014/11/21. doi: 10.1126/scitranslmed. 3009885 PMID: 25411472.